152 related articles for article (PubMed ID: 37468265)
1. FGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review.
Kato H; Kimura S; Taguchi M; Sunouchi T; Hoshino Y; Hidaka N; Edvige Foligno N; Koga M; Manaka K; Tamiya H; Kawakami M; Kage H; Yasunaga Y; Nangaku M; Makita N; Ito N
Endocr J; 2023 Oct; 70(10):1005-1013. PubMed ID: 37468265
[TBL] [Abstract][Full Text] [Related]
2. Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
Tantisattamo E; Ng RC
Hawaii Med J; 2011 Jul; 70(7):139-43. PubMed ID: 21886301
[TBL] [Abstract][Full Text] [Related]
3. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
4. FGF23-Associated Tumor-Induced Osteomalacia in a Patient With Small Cell Carcinoma: A Case Report and Regulatory Mechanism Study.
Sauder A; Wiernek S; Dai X; Pereira R; Yudd M; Patel C; Golden A; Ahmed S; Choe J; Chang V; Sender S; Cai D
Int J Surg Pathol; 2016 Apr; 24(2):116-20. PubMed ID: 26612848
[TBL] [Abstract][Full Text] [Related]
5. Hypophosphatemia related to a neuro-endocrine tumor of the pancreas: A case report.
Pickering ME; Bouvier D; Puravet A; Soubrier M; Sapin V; Oris C
Clin Biochem; 2022 Jun; 104():62-65. PubMed ID: 35337828
[TBL] [Abstract][Full Text] [Related]
6. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
7. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.
Hidaka N; Kato H; Koga M; Katsura M; Oyama Y; Kinoshita Y; Fukumoto S; Makita N; Nangaku M; Ito N
Bone Rep; 2021 Dec; 15():101144. PubMed ID: 34901334
[TBL] [Abstract][Full Text] [Related]
8. The pathophysiology of hypophosphatemia.
Ito N; Hidaka N; Kato H
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101851. PubMed ID: 38087658
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer-related hypophosphatemic osteomalacia--a case report.
Lin HA; Shih SR; Tseng YT; Chen CH; Chiu WY; Hsu CY; Tsai KS
J Clin Endocrinol Metab; 2014 Dec; 99(12):4403-7. PubMed ID: 25181387
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Prostate Cancer with Multiple Bone Metastasis with High FGF23 Value Indicated by Intractable Hypocalcemia and Hypophosphatemia].
Nishida S; Shigesawa I; Nagai S; Itoh N; Masumori N
Hinyokika Kiyo; 2021 Jan; 67(1):47-51. PubMed ID: 33535298
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria.
Velazquez-Navarro JA; Loya-Teruel E; Rios-Gomez M; Montes-Ramirez JE
Cureus; 2022 Jan; 14(1):e20893. PubMed ID: 35145798
[TBL] [Abstract][Full Text] [Related]
12. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
15. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
16. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
18. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
19. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
[TBL] [Abstract][Full Text] [Related]
20. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
